THE HAGUE, Dec 2 (AFP) - A request by Libya to convert chemical weapons production facilities into a pharmaceuticals plant has been given the go-ahead by an international weapons watchdog.
The Organisation for the Prohibition of Chemical Weapons (OPCW) said on Thursday it had approved a scheme to covert the facilities into a plant that could produce low-cost medecine against AIDS and malaria for the African market.
"These vaccines are urgently required in the treatment of AIDS/HIV, malaria and tuberculosis," a statement by the organization, which is based in the Dutch capital, said.
The plant at Rabta produced about 100 tonnes of sulphur mustard gas and other nerve agents in the 1980s. It was closed in 1990 after the United States and others accused Libya of using the facility for nefarious purposes and hinted at action to stop it.
Libya on January 6 agreed to adhere to the Chemical Weapons Convention following Tripoli's decision to give up its weapons of mass destruction development programme.
041202
AF041237
©AFP 2004.. All Rights Reserved. AFP articles contained on the AEGiS web site may not be reproduced, distributed, transmitted, displayed, published or broadcast without AFP's prior written permission. You may make one copy of each article for your personal, non-commercial use only; more copies would require AFP's prior written permission. http://www.afp.com/
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, the National Library of Medicine, Bridgestone Firestone Trust Fund, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
©1990, 2004 - AEGiS. AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
